Back to search

Ireland· IE-PA-EU/1/20/1455/004-006

Piqray 50 mg film-coated tablets Piqray 200 mg film-coated tablets

A alpelisib product containing alpelisib, registered in Ireland by Novartis Europharm Limited.

ATC L01XX65

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedPiqray 50 mg film-coated tablets Piqr…ATCL01XX65REGISTER NO.IE-PA-EU/1/20/1455/00…PACKS LISTED1CHECKEDSeptember 28, 2026

The record

At a glance

HPRA (Ireland)
Active substance
Alpelisib
Manufacturer
Novartis Europharm Limited
Country
Ireland (IE)
ATC code
L01XX65
ATC class
Alpelisib
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/20/1455/004-006

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

347 interactions on record for alpelisib.

Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Alpelisib · interactions on record

347 records

  • 14 severe
  • 329 moderate
  • 4 minor

Most severe, free to view

  • EdoxabanB01AF03severe
  • RifampicinJ04AB02severe
  • RifabutinJ04AB04severe
  • RifapentineJ04AB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Alpelisib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All alpelisib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Piqray, Vijoice
  • Liechtenstein · Piqray, Vijoice
  • Norway · Piqray, Vijoice

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3ee71b64-3829-4710-b4bc-dd73ef566f89
GET /v1/drugs/3ee71b64-3829-4710-b4bc-dd73ef566f89?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XX65"
  ],
  "strength": null,
  "pa_number": "EU/1/20/1455/004-006",
  "substances": [
    "Alpelisib"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "27/07/2020",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about alpelisib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.